Sixty adults with Alzheimer's disease each spent a single night in a sleep laboratory in Catalonia, Spain, wired up to machines that tracked every brain wave. The next morning, researchers drew fluid from their spines to measure a chemical called orexin. Then they followed the group for three years. What they found could change how we think about sleep, memory, and one of the world's most feared diseases.
Orexin is a brain chemical that helps regulate two everyday things: sleep and appetite. It keeps us awake, and it tells us when to eat. Too little orexin causes a rare illness called narcolepsy, where people suddenly fall asleep. But this study, led by researchers at Concordia University in Montreal and published in the journal Neurology, reveals the opposite problem too: too much orexin makes the brain more vulnerable to Alzheimer's disease.
The team found that people with higher levels of orexin in their cerebrospinal fluid—the clear liquid that cushions the brain and spinal cord—showed more cognitive decline over the three years. They had poorer memory and thinking, more severe behavioral and psychiatric symptoms, and higher levels of biological markers linked to neurodegeneration and inflammation.
But here is the encouraging twist. That harmful relationship was softened by specific brain waves during deep, nonrapid eye movement (NREM) sleep. Participants who produced stronger sleep spindles and slow oscillations—two types of brain waves tied to memory support and protection—showed less cognitive decline over time, even when their orexin levels were high. In plain terms, a good night's deep sleep acted like a shield inside the brain.
"Just as too little orexin is associated with diseases like narcolepsy, too much orexin can lead to higher vulnerability to Alzheimer's," says Thanh Dang-vu, a neurologist and professor at Concordia and a study co-author.
The data were gathered by researchers at the Universitat de Lleida in Catalonia. After the overnight sleep recordings and spinal fluid samples, participants completed cognitive and neuropsychiatric assessments at regular intervals for the next three years. This long view matters because Alzheimer's unfolds slowly, like a very long movie. "Alzheimer's disease is a moving target," says co-first author Arsenio Paez, a postdoctoral researcher at Concordia's Sleep, Cognition and Neuroimaging Laboratory. "We can see how the course of people's Alzheimer's disease changes over time."
The most exciting part may be what comes next. Drugs that block orexin are already used to treat insomnia, and scientists are exploring them as possible Alzheimer's therapies. This study suggests that monitoring sleep spindles, slow oscillations, and orexin levels could help doctors measure how the disease is progressing—and identify which patients might benefit from specialized treatment.
"New ways to potentially act on sleep to slow the progression of Alzheimer's disease" are on the horizon, Dang-vu says. For millions of families facing this disease, the promise that a deep, restful sleep might protect the brain is a hopeful—and surprisingly simple—place to start.